Avricore Health Announces Stock Option Grant for 4,100,000 Common Shares
ByAinvest
Saturday, Jun 14, 2025 1:09 am ET1min read
AVGR--
The options will vest quarterly and expire in five years, provided that the optionees continue to act as directors, officers, employees, or consultants of the company. This move is part of Avricore's strategy to incentivize and retain key personnel as it continues to develop and expand its flagship offering, HealthTab, a network of rapid testing devices in community pharmacies [1].
HealthTab combines best-in-class point-of-care technologies with a secure, cloud-based platform, enabling lab-accurate results from a few drops of blood and real-time data reporting. The system includes up to 23 key biomarkers for chronic disease management and has recently added capabilities for bacterial and viral tests, such as strep and COVID-19 [1].
Avricore Health Inc. aims to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies. The HealthTab network model empowers pharmacists to play a greater role in primary care delivery while reducing costs and waiting times and providing multiple revenue streams [1].
The company's stock price has seen recent growth, with a 10% increase on June 13, 2025, closing at CAD $0.0550 [2].
References:
[1] https://www.streetinsider.com/Globe+Newswire/Avricore+Grants+Options/24937445.html
[2] https://ca.finance.yahoo.com/quote/AVCR.V/analysis/
AVRE--
Avricore Health Inc. has granted stock options for 4,100,000 common shares to its directors, officers, employees, and consultants at a price of CAD $0.05 per share. The options will vest quarterly and expire in 5 years. This move is part of Avricore's strategy to advance pharmacy practice and patient care through its flagship offering HealthTab, a network of rapid testing devices in community pharmacies.
Avricore Health Inc. (TSXV: AVCR), a pharmacy service innovator focused on advancing pharmacy practice and patient care, has announced the granting of stock options to its directors, officers, employees, and consultants. The company's board of directors approved the issuance of 4,100,000 common shares at an exercise price of CAD $0.05 per share [1].The options will vest quarterly and expire in five years, provided that the optionees continue to act as directors, officers, employees, or consultants of the company. This move is part of Avricore's strategy to incentivize and retain key personnel as it continues to develop and expand its flagship offering, HealthTab, a network of rapid testing devices in community pharmacies [1].
HealthTab combines best-in-class point-of-care technologies with a secure, cloud-based platform, enabling lab-accurate results from a few drops of blood and real-time data reporting. The system includes up to 23 key biomarkers for chronic disease management and has recently added capabilities for bacterial and viral tests, such as strep and COVID-19 [1].
Avricore Health Inc. aims to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies. The HealthTab network model empowers pharmacists to play a greater role in primary care delivery while reducing costs and waiting times and providing multiple revenue streams [1].
The company's stock price has seen recent growth, with a 10% increase on June 13, 2025, closing at CAD $0.0550 [2].
References:
[1] https://www.streetinsider.com/Globe+Newswire/Avricore+Grants+Options/24937445.html
[2] https://ca.finance.yahoo.com/quote/AVCR.V/analysis/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet